Like a lot of clinicians, I worried about how the rise of AI might impact my field. I’m not opposed to innovation, but in healthcare, new tools have consequences when

Two North Carolina-based health systems, Atrium Health and WakeMed Health, announced plans to merge last week. As part of the proposed deal, Atrium plans to invest $2 billion into WakeMed

UCB is adding a big piece to its immunology pipeline with a multi-billion dollar deal to buy Candid Therapeutics, a clinical-stage biotech company developing therapies in a promising but competitive

Patient care may be the priority, but it’s only half the equation for healthcare facilities that also need to maintain financial organization and stability to support that care. So, why

Last summer, CVS and Mass General Brigham announced a deal they promised would expand access to primary care. Now, a state regulator is warning that not only is that outcome

The biotech IPO window looks like it’s reopening. This past week closed with three biotech companies joining the public markets, a flurry of activity that helped make April the biggest

From how deals get sourced to how capital allocators think, generative AI is reshaping how venture capital works. For many, it’s seen as a positive, and there are truly great

What do diabetes, obesity, chronic kidney disease, liver disease, cardiovascular disease, and even some cancer have in common? They are all metabolic conditions – sometimes caused, or worsened by poor

For years, healthcare treated AI as a series of separate bets. We had one tool for documentation, another for remote monitoring, and a handful for imaging. This fragmented approach mirrored

Here is the central absurdity of clinical Digital Out-of-Home (DOOH): screen owners have constructed the most intentful advertising environment in healthcare — a captive, health-focused audience, sitting with a specific